Our Process
Multi-omic Data
Generating patient-derived clinical metadata and biospecimen samples
AI
Predicting viable biomarkers and therapeutic candidates
Synthetic Biology
Production of small molecules via cell-free expression
Functional Screening
High throughput immune-profiling assays
We are using proprietary methods in genomic sequencing, artificial intelligence, and synthetic biology to discover biomarkers and novel therapeutics for the most challenging immunologic disorders.
Team
Ana Vega Rodríguez, PhD
Research Scientist
Ayin Vala, MS
Co-founder, Chief AI Officer
Claire Toney, BS
Research Assistant
Dora Yu, PhD
Scientist
Jesus Barajas, PhD
Head of Natural Product Discovery
Kareem Barghouti, MBA
Co-founder, CEO
Lanying Ma, PhD
Senior Bioinformatics Scientist
Mark Ashwell, PhD
Head of Chemistry
Nehal Hedge
Research Assistant
Nora Fritz, MBA
Strategy and Operations Manager
Peter McCaffrey, MD
Co-founder, CTO
Riccardo Guidi, PhD
Head of Immunology Research
Subramanya Rao, PhD
Scientist
Alex Cogdill, PhD
Cancer Immunology
Stephen Nayfach, PhD
Bioinformatics
Tomer Altman, PhD
Bioinformatics
Advisors
Elaine Stracker, JD, PhD
Former EVP & General Counsel at Pharmacyclics
Grazia Piizzi, PhD
Former Executive Director at Merck
Ken Blount, PhD
CSO Rebiotix
Kovi Bessoff, MD, PhD
Co-founder
Mohamed Donia, PhD
Associate Professor, Princeton University
Mohan Iyer, MBA
General Partner, SOSV/IndieBio
Milad Alucozai, MS, MPH
Serial Entrepreneur, Advisor to AstraZeneca
Nadim Ajami, PhD
Executive Director of Microbiome at MD Anderson
Phil Jones, PhD
VP of Therapeutic Discovery at MD Anderson
Wasim Malik, PhD
Managing Partner at Iaso, Former CDO at Roivant
Supported By
Partners
Contact Us
LOCATION
280 Utah Ave. South San Francisco, CA
PHONE
(650) 479-5539
info@pragmabio.com